NCT06033547View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

May 13, 2027

Study Completion Date

May 13, 2027

Conditions
HIV Infections
Interventions
DRUG

Cabotegravir Formulation F

Cabotegravir Formulation F will be administered

DRUG

Cabotegravir Formulation G

Cabotegravir Formulation G will be administered

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT06033547 - A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants | Biotech Hunter | Biotech Hunter